RCKT Filings — Rocket Pharmaceuticals, Inc. - FilingSpy
RCKT
Rocket Pharmaceuticals, Inc.
A developer of gene therapies for rare, life-threatening genetic diseases, Rocket Pharmaceuticals works to correct the underlying genetic defects behind conditions like Danon disease and leukocyte adhesion deficiency. Founded in 2015 and merged with Inotek Pharmaceuticals in 2018, the company's name reflects its "moonshot" ambition to bring speed to medicine. Its therapies either modify a patient's own blood stem cells outside the body or deliver corrected genes directly via engineered viruses.
Rocket swings to a $123.2M net profit on a $178.2M gain from selling a priority review voucher.
Rocket Pharmaceuticals reported its first quarterly profit. reached $123.2 million, driven entirely by a $178.2 million gain on the sale of a , while operating expenses fell 34% to $46.9 million after a 2025 restructuring. The company remains pre- from product sales, with its cash runway now extended into 2028.
Key takeaways
The company reported of $123.2 million, compared to a net loss of $68.9 million a year ago, as a $178.2 million gain from the sale of a (PRV) more than offset operating expenses.
Total operating expenses fell 34% to $46.9 million, reflecting the full impact of the July 2025 restructuring that reduced the workforce by approximately 30%.
Research and development expenses dropped $13.2 million to $29.5 million, driven by lower headcount, reduced manufacturing costs, and a strategic prioritization of cardiovascular gene therapy programs.
Section summaries
Management's Discussion and Analysis
Rocket swung to net income on a $178.2M PRV sale gain while R&D and G&A costs fell sharply after a 2025 restructuring.
⌄
Total operating expenses fell 34% to $46.9M in Q2 2026, driven by lower R&D headcount, reduced manufacturing costs, and decreased commercial preparation spending.
R&D expense dropped $13.2M to $29.5M, with direct program costs declining across Danon disease, LAD-I, and FA as the company prioritized cardiovascular gene therapies.
General and administrative expenses decreased $7.6 million to $17.4 million, primarily from reduced commercial preparation spending and lower headcount following the workforce reduction.
Cash, cash equivalents, and investments rose to $283.7 million at quarter-end from $188.9 million at year-end 2025, boosted by the PRV sale proceeds, and management projects this will fund operations into the second quarter of 2028.
The FDA approved KRESLADI in March 2026, the company's first product, but management does not expect material near-term due to the ultra-rare patient population.
What changed
The FDA approved KRESLADI by its March 28, 2026 PDUFA date, resolving the key watch item from the FY 2025 annual report and marking the company's first product approval.
The planned $180 million PRV sale flagged in Q1 FY2026 was completed, generating a $178.2 million gain and extending the cash runway into the second quarter of 2028, up from the prior guidance of Q2 2027.
The consolidated securities class action and derivative suit regarding the RP-A501 trial remain in early stages; a motion to dismiss was filed in January 2026 with briefing completed in May 2026, and the derivative suit is stayed, unchanged from the prior quarter's update.
No update was provided on a regulatory filing timeline for RP-A501 in Danon Disease or on securing a partner for the deprioritized Fanconi Anemia and PKD programs, items previously flagged to watch.
What to watch
The rate of quarterly cash consumption against the $283.7 million balance, to assess whether the extended runway into the second quarter of 2028 remains on track as the company continues to fund operations without product .
Any update on a regulatory filing timeline for RP-A501 in Danon Disease, now that the clinical hold is lifted and a recalibrated dose is authorized.
The outcome of the motion to dismiss the consolidated securities class action, which could affect management attention and potential liability.
Progress in securing a partner for the deprioritized Fanconi Anemia and PKD programs, which the company is seeking to out-license.
G&A expense decreased $7.6M to $17.4M, reflecting lower commercial launch spending and reduced headcount following the 2025 workforce reduction.
The $180M sale of a Priority Review Voucher generated a $178.2M gain, turning a $68.9M pre-tax loss in Q2 2025 into $131.8M in pre-tax income.
Cash, equivalents, and investments totaled $283.7M at quarter-end, which management expects will fund operations into the second quarter of 2028.
KRESLADI™ received accelerated FDA approval in March 2026, but the company does not expect material near-term given the ultra-rare patient population.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk related to changes in interest rates. As of June 30, 2026 and December 31, 2025, we had cash, cash equivalents and investments of $283.7 million and $188.9 million, respectively. The Company’s investments are primarily in U.S. Treasury Securities. O…
⌄
We are exposed to market risk related to changes in interest rates. As of June 30, 2026 and December 31, 2025, we had cash, cash equivalents and investments of $283.7 million and $188.9 million, respectively. The Company’s investments are primarily in U.S. Treasury Securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in U.S. interest rates and our investments that can decline in value if market interest rates increase. We do not utilize interest rate hedging agreements or other interest rate derivative instruments.
If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at June 30, 2026, the net effect on the net fair value of our investments would have resulted in a hypothetical decline of $0.1 million. While we believe our cash, cash equivalents, and marketable securities do not contain excessive risk, we cannot provide absolute assurance that, in the future, our investments will not be subject to adverse changes in market value.
46
Table of Contents
Rocket Pharmaceuticals faces consolidated securities class action and a derivative suit over RP-A501 trial disclosures.
⌄
Two putative securities class actions were consolidated in September 2025, alleging misstatements and omissions about the Phase 2 trial of RP-A501 for Danon disease.
The consolidated amended complaint covers purchasers from February 28, 2024 through August 25, 2025 and claims the stock price was inflated by undisclosed and protocol changes.
A the consolidated securities complaint was filed in January 2026, with briefing completed in May 2026; the company intends to defend vigorously.
A putative filed in October 2025 largely parallels the securities claims and adds allegations of inadequate internal controls and insider trading.
The derivative suit is stayed until the securities class action motions to dismiss are resolved, and the company will pay the officers' and directors' legal fees.
The company cannot predict the outcome or estimate potential loss for either matter, and states no other material proceedings exist.
Our material risk factors are disclosed in Item 1A of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed in such filing.
⌄
Our material risk factors are disclosed in Item 1A of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed in such filing.